Elsevier

Gynecologic Oncology

Volume 86, Issue 2, August 2002, Pages 118-123
Gynecologic Oncology

Regular Article
Hormone Replacement Therapy Formulations and Risk of Epithelial Ovarian Carcinoma

https://doi.org/10.1006/gyno.2002.6746Get rights and content

Abstract

Objective. Hormone replacement therapy (HRT) has been inconsistently linked to ovarian cancer. Estrogen formulations in HRT vary in their effects on estrogen-sensitive target tissues, such as the ovary. The aim of the study is to evaluate the impact of various HRT formulations and their characteristics of use on the risk of epithelial ovarian carcinoma (EOC).

Methods. We assessed the association between the use of HRT and the risk of invasive EOC in women participating in a population-based, case-control study conducted in the Delaware Valley from 1994 to 1998. Cases aged 45 or above at diagnosis (n = 484) were compared to community controls (n = 926) frequency matched by age and area of residence. Information on HRT formulation, timing, and duration were obtained by in-person interview by trained interviewers. HRT formulations were classified as opposed (estrogen + progestin) or unopposed (estrogen alone). They were further categorized according to the estrogen component as either conjugated equine estrogen (CEE), the most common formulation, or non-CEE. Multivariate unconditional logistic regression analyses were used to adjust for age at diagnosis, number of live births, use of oral contraceptives, family history of ovarian carcinoma, and history of tubal ligation.

Results. Overall, no association was found between any use of HRT and EOC. Although use of unopposed non-CEE was associated with a significant decrease in risk among hysterectomized women (OR = 0.17, 95%CI = 0.04,0.82), this was not true for women with an intact uterus (OR = 1.14, 95%CI = 0.44,2.98; P for interaction = 0.049). No significant differences in EOC risk were observed for other HRT formulations.

Conclusions. Our results did not suggest any consistent pattern of altered risk for EOC and the overall use of HRT by specific formulations of HRT.

References (50)

  • F Grodstern et al.

    Post menopausal estrogen and progestin use and the risk of cardiovascular disease

    N Engl J Med

    (1996)
  • P Ryan et al.

    Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis

    Br J Obstet Gynaecol

    (1992)
  • D Cramer et al.

    Determinants of ovarian cancer risk. I. Reproductive experience and family history

    J Natl Cancer Inst

    (1983)
  • A Polychronopoulou et al.

    Reproductive variables, tobacco, ethanol, coffee, and somatometry as risk factors for ovarian cancer

    Int J Cancer

    (1993)
  • A Whittemore et al.

    Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies, II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group

    Am J Epidemiol

    (1992)
  • D Kaufman et al.

    Noncontraceptive estrogen use and epithelial ovarian cancer

    Am J Epidemiol

    (1989)
  • N Hildreth et al.

    An epidemiologic study of epithelial carcinoma of the ovary

    Am J Epidemiol

    (1981)
  • M Booth et al.

    Risk factors for ovarian cancer: A case-control study

    Br J Cancer

    (1989)
  • N Weiss et al.

    Noncontraceptive estrogen use and the occurrence of ovarian cancer

    J Natl Cancer Inst

    (1982)
  • P Hartge et al.

    Menopause and ovarian cancer

    Am J Epidemiol

    (1998)
  • J Annergers et al.

    Ovarian cancer: Incidence and case-control study

    Cancer

    (1979)
  • E Negri et al.

    Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies

    Int J Cancer

    (1999)
  • M Goodman et al.

    Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism

    Cancer Epidemiol Biomarkers Prev

    (2001)
  • M Lantta

    Estradiol and progesterone receptors in normal ovary and ovarian tumors

    Acta Obstet Gynecol Scand

    (1984)
  • Cited by (60)

    • Menopause and Aging

      2019, Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management: Eighth Edition
    • Menopause and Aging

      2013, Yen and Jaffe's Reproductive Endocrinology: Seventh Edition
    • Menopause and aging

      2009, Yen & Jaffe's Reproductive Endocrinology: Expert Consult - Online and Print
    • Menopause and Aging

      2009, Yen & Jaffe's Reproductive Endocrinology
    • Estrogen and progestogen therapy in postmenopausal women

      2008, Fertility and Sterility
      Citation Excerpt :

      Increased duration of ET use for 10 or more years was associated with a significantly increased risk of ovarian cancer (RR 1.8; 95% CI, 1.1–3.0). In a 2002 American case-control study, adjusted ORs for invasive epithelial ovarian cancer were 0.90 (95% CI, 0.61–1.33) with ever-use of conjugated estrogens and 0.52 (95% CI, 0.25–1.10) with other estrogens (109). Odds ratios for HT with ever-use of progestogens combined with conjugated estrogens and other estrogens were 1.06 (95% CI, 0.74–1.52) and 1.08 (95% CI, 0.59–2.00), respectively.

    • Hormone replacement therapy and ovarian cancer risk: A meta-analysis

      2008, Gynecologic Oncology
      Citation Excerpt :

      Nineteen case–control studies were included in our meta-analysis (involving 8240 case patients and 20,996 control subjects). Table 2 summarizes the characteristics of these case–control studies [37–55]. Since too few studies are evaluating current or former hormone use, we just calculated the summary estimate of ever HRT use.

    View all citing articles on Scopus
    View full text